Recommend Epigenetics to your librarian today. Download form here.
Sign up for Table of Contents Alerts.
The official journal of the Epigenetics Society.
Email this page
Print this page
Research Paper
CD44 and PTGS2 Methylation are Independent Prognostic Markers for Biochemical Recurrence Among Prostate Cancer Patients with Clinically Localized Disease
Karen Woodson, Keith J O’Reilly, David E Ward, Jack Walter, Jeffery Hanson, Elyse L Walk and Joseph A Tangrea
volume 1 | issue 4
october/november/ december 2006Pages: 183 - 186
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.
Up to 30% of men with clinically localized disease who receive radical prostatectomy develop a biochemical recurrence. Gene methylation in tumor tissue may distinguish men with aggressive cancer. This study evaluated methylation of GSTP1, RARβ2, CD44 and PTGS2 with biochemical recurrence among 60 patients who underwent radical prostatectomy using logistic regression and Kaplan Meier time to event analysis. Methylation of GSTP1 and RARβ2 was not associated with recurrence, however, CD44 and PTGS2 methylation were significant predictors. In multivariate models adjusting for Gleason grade, methylation profile of CD44 and PTGS2 combined was an independent predictor of biochemical recurrence (associated with 9-fold increased risk). In addition, Kaplan Meier analysis showed CD44 and PTGS2 methylation was associated with shorter time to recurrence. CD44 and PTGS2 methylation may predict biochemical recurrence in prostate cancer patients undergoing radical prostatectomy and if validated in larger studies, may identify patients with aggressive cancer.
Authors
Karen Woodson
National Cancer Institute, Bethesda, Maryland
Keith J O’Reilly
Madigan Army Medical Center, Tacoma, WA
David E Ward
Madigan Army Medical Center, Tacoma, WA
Jack Walter
Madigan Army Medical Center, Tacoma, WA
Jeffery Hanson
National Cancer Institute, Bethesda, Maryland
Elyse L Walk
National Cancer Institute, Bethesda, Maryland
Joseph A Tangrea
National Cancer Institute, Bethesda, Maryland
We now provide open access to journal articles published online for one year or more. This article may be downloaded at the following link:
Download PDF If the document does not open, please right-click on the link (control-click on a Macintosh) and select the option to save the file to disk.